Biosimilars for Retinal Diseases: An Update

被引：29

作者：

Sharma, Ashish ^{[1
]}

Kumar, Nilesh ^{[1
]}

Parachuri, Nikulaa ^{[1
]}

Bandello, Francesco ^{[2
]}

Kuppermann, Baruch D. ^{[3
]}

Loewenstein, Anat ^{[4
]}

机构：

[1] Lotus Eye Hosp & Inst, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India

[2] Univ Vita Salute, Sci Inst San Raffaele, Milan, Italy

[3] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA

[4] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel

来源：

AMERICAN JOURNAL OF OPHTHALMOLOGY | 2021年 / 224卷

关键词：

MACULAR DEGENERATION; RANIBIZUMAB; THERAPY;

D O I：

10.1016/j.ajo.2020.11.017

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

endothelial growth factor agents for retinal diseases and provide an update about their development. ? DESIGN: Literature review. ? METHODS: A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. ? RESULTS: To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. ? CONCLUSION: Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions. (Am J Ophthalmol 2021;224:36?42. ? 2020 Elsevier Inc. All rights reserved.)

引用

页码：36 / 42

页数：7

共 50 条

[21] An Update on the Registration of Biosimilars in Malaysia
Khoo, Yvonne Siew Khoon
Tang, Tien Yew
Goh, Pick Sim
Halimi, Hazureen Mohd
Ab Ghani, Azizah
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (01) : 55 - 59
[22] BIOSIMILARS IN THE UK A 2018 UPDATE
Hendrich, J.
VALUE IN HEALTH, 2018, 21 : S85 - S85
[23] Biosimilars in the Treatment of Psoriasis: An Update
Puig, L.
Carrascosa, J. M.
Notario, J.
ACTAS DERMO-SIFILIOGRAFICAS, 2020, 111 (10): : 809 - 814
[24] An Update on the Registration of Biosimilars in Malaysia
Yvonne Siew Khoon Khoo
Tien Yew Tang
Pick Sim Goh
Hazureen Mohd Halimi
Azizah Ab Ghani
Therapeutic Innovation & Regulatory Science, 2017, 51 : 55 - 59
[25] Biosimilars in rheumatic diseases
Hajji, Raouf
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (03)
[26] Biosimilars in allergic diseases
Ferrando, Matteo
Bagnasco, Diego
Braido, Fulvio
Varricchi, Gilda
Canonica, Giorgio W.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 16 (01) : 68 - 73
[27] Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review
Hariprasad, Seenu M.
Holz, Frank G.
Asche, Carl V.
Issa, Amine
Mora, Oriol
Keady, Simon
Rezk, Mourad F.
Sarocco, Phil
Simoens, Steven
OPHTHALMOLOGY AND THERAPY, 2025, 14 (04) : 621 - 641
[28] Aflibercept biosimilars – update on the development progress
Ashish Sharma
Anat Loewenstein
Nilesh Kumar
Nikulaa Parachuri
Francesco Bandello
Baruch D. Kuppermann
Eye, 2024, 38 : 824 - 825
[29] Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
Grzybowski, Andrzej
Markeviciute, Agne
Zemaitiene, Reda
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
[30] Update on Viral Gene Therapy Clinical Trials for Retinal Diseases
Cheng, Shun-Yun
Punzo, Claudio
HUMAN GENE THERAPY, 2022, 33 (17-18) : 865 - 878

← 1 2 3 4 5 →